Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of JT001 (VV116) in Participants With Mild to Moderate COVID-19

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deuremidevir hydrobromide (Primary)
Indications COVID 2019 infections
Focus Registrational; Therapeutic Use
Acronyms JT001-015
Sponsors Shanghai Vinnerna Biosciences

Most Recent Events

10 Jan 2025 Results presented in the Junshi Biosciences - Impact Therapeutics (JV) Media Release.
23 Nov 2023 According to Junshi Biosciences - Impact Therapeutics (JV) media release, final results from this trial were published in the Lancet Infectious Diseases.
23 Nov 2023 Results presented in the Junshi Biosciences - Impact Therapeutics (JV) Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com